Latest Intelligence on Therapy Area in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Solid tumor market: potential lies in targeted therapies

Published By Datamonitor
09 Nov 2007
CommentWire
CommentWire

Shire: blockbuster and beyond for Vyvanse

Strong Q1 sales and significant velocity for its ADHD product Vyvanse suggest that Shire will be heralding a new blockbuster by the end of the year. Furthermore, with approval pending in European markets and investigations into additional psychiatric indications providing promising results, Vyvanse is set to deliver long-term sales growth.

Published By Datamonitor
30 Apr 2012
CommentWire
CommentWire

Shionogi/ViiV Healthcare: novel HIV cross-class combination enters battle to become market leader

Shionogi and ViiV Healthcare are investigating the safety and efficacy of new cross-class fixed-dose combination 572-Trii in a Phase III study, dubbed SINGLE. The candidate is the companies' best bet to break the current dominance of Atripla in HIV first-line therapy, and represents the ongoing movement toward tolerability as a key differentiating factor in HIV treatment.

Published By Datamonitor
08 Feb 2011
CommentWire
CommentWire

Servier: new Protelos data highlight shifting focus in osteoporosis research

As one of the lead sponsors of this year's World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, Servier presented new data for its dual action drug Protelos. Discussion of the therapy led on to the importance of companies using bone quality assessment, rather than relying on measurements of bone mineral density.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Servier/Novartis: potential blockbuster Valdoxan is set to lead the market

Pooled analysis of four major studies of Valdoxan has shown significantly greater efficacy and an increased percentage of responders than conventional depression treatments. Due to its novel mechanism of action, strong efficacy profile, increased tolerability and potential to alleviate comorbid sleep disturbances, Valdoxan is well positioned to become a leading treatment in the depression market.

Published By Datamonitor
03 Sep 2010
ResearchWire
ResearchWire

Schizophrenia: generics influx set to damage revenues

Published By Datamonitor
02 Oct 2006
Expert View
Expert View

RSV: lack of vaccine puts most vulnerable at risk

An infection with the respiratory syncytial virus can result in hospitalization and sometimes respiratory failure. With no suitable treatment available and the only preventative medication considered too expensive to be widely prescribed, the need for an effective vaccine is high. However, given the failure of recent developmental efforts the launch of a successful vaccine is still some time away.

Published By Datamonitor
18 Apr 2007
CommentWire
CommentWire

Roche: Tamiflu sales hit by fading flu hype

Sales of Tamiflu, Roche's influenza treatment, have plummeted by 68% compared to 2007, reflecting the waning attention paid to pandemic preparation by governments worldwide and the emerging competition from Relenza and pandemic influenza vaccines. Despite insufficient stockpiles in most countries, Datamonitor believes that the seasonal market will continue to gain importance for Tamiflu's sales.

Published By Datamonitor
05 Feb 2009
CommentWire
CommentWire

Roche: novel Herceptin formulation promises greater convenience

Having stepped up lifecycle management for its leading breast cancer monoclonal antibody, Herceptin, Roche hopes to encourage uptake of a more convenient formulation of the drug. This strategy could help to conserve its share of an increasingly competitive market, but may be challenging to implement due to concerns over compliance and financial incentives to prescribe intravenous cancer drugs.

Published By Datamonitor
22 Jan 2010
CommentWire
CommentWire

Roche: new MabThera data challenges anti-TNFs

New data from Roche's IMAGE study presented at the European League Against Rheumatism congress show that administering MabThera at first-line may significantly slow joint damage and improve clinical outcomes in patients with rheumatoid arthritis. However, Datamonitor does not predict that these data will change the current treatment paradigms, as touted by the investigators.

Published By Datamonitor
12 Jun 2009

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.